|

Docetaxel Injection Clinical Trials

9 actively recruiting trials

▲ +1 trial since August 2026

Also known as: Docetaxel

Pipeline

Phase 1: 1Phase 2: 3Phase 3: 3Phase 1/2: 1Phase 2/3: 1

Top Sponsors

  • Jiangsu HengRui Medicine Co., Ltd.2
  • Shanghai Miracogen Inc.1
  • Shanghai JMT-Bio Inc.1
  • Nanjing Leads Biolabs Co.,Ltd1
  • LaNova Medicines Limited1

Indications

  • Cancer9
  • Breast Cancer2
  • Advanced or Metastatic Urothelium Cancer1
  • Advanced Solid Tumour1
  • Advanced Prostate Cancer1

Other9 trials

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Phase 2
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
Phase 1/2
A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors
Phase 2
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
Phase 3
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
Phase 3
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Phase 2
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Phase 3
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Phase 2/3
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.